Dose modulation strategies in patients with psoriasis: real-world comparison between secukinumab and brodalumab for up to 1 year after dose spacing Article Swipe
Luca Mastorino
,
Paolo Dapavo
,
Michela Ortoncelli
,
Eleonora Bongiovanni
,
Yingying Liao
,
Margherita Pelucchi
,
Francesco Leo
,
Pietro Quaglino
,
Simone Ribero
·
YOU?
·
· 2025
· Open Access
·
· DOI: https://doi.org/10.1093/ced/llaf250
YOU?
·
· 2025
· Open Access
·
· DOI: https://doi.org/10.1093/ced/llaf250
Background Modulating the regimen of biologics is of increasing interest in patients with psoriasis. This includes dose reduction (de-escalation) and dose augmentation (escalation). De-escalation strategies include reducing the single therapeutic dose, the mg kg−1 ratio or the number of injections, and dose spacing (D-S), extending the interval between administrations. Real-life data regarding dose de-escalation are lacking. Objectives To retrospectively analyse the effectiveness and drug survival of D-S of secukinumab and brodalumab in a real-world setting. Methods This is a cohort study with retrospective analysis of the general characteristics of patients with psoriasis undergoing therapeutic biologic D-S with secukinumab or brodalumab and the effectiveness of D-S. Results Eighty patients underwent dose modulation by D-S with the interval increased by 50% of the approved range. Overall, 31 (39%) were treated with secukinumab and 49 (61%) with brodalumab. After a mean of 35 months, the population underwent D-S. At D-S, the mean Psoriasis Area and Severity Index (PASI) was 0.1, ranging from 0.7 to 0.1 in the following year. PASI 100 (100% improvement) was achieved by 91% at the date of D-S and remained stable over the following year. Similar trends were seen for PASI 90 and absolute PASI ≤ 1, with 99% and 100% of patients, respectively, achieving these goals at the time of D-S. These levels were maintained at 12 months after D-S. The 12-month drug survival of the D-S regimen was 66%, with one-quarter of patients (20 of 80) returning to the standard dosage. PASI 100 was regained in two-thirds of these cases. Secukinumab showed a drug survival after D-S of 78%, compared with 59% for brodalumab. No differences in mean and relative PASI scores at any timepoint after D-S were found between the two treatments. Conclusions Therapeutic modulation of interleukin-17 inhibitors in patients with psoriasis and controlled disease seems an effective therapeutic strategy that maintains efficacy for up to 1 year in 40% of patients. No differences were observed between secukinumab and brodalumab during the D-S regimen.
Related Topics
Concepts
Secukinumab
Medicine
Dermatology
Psoriasis
Plaque psoriasis
Ixekizumab
Pharmacology
Psoriatic arthritis
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.1093/ced/llaf250
- https://academic.oup.com/ced/advance-article-pdf/doi/10.1093/ced/llaf250/63472727/llaf250.pdf
- OA Status
- hybrid
- References
- 18
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4411194368
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4411194368Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1093/ced/llaf250Digital Object Identifier
- Title
-
Dose modulation strategies in patients with psoriasis: real-world comparison between secukinumab and brodalumab for up to 1 year after dose spacingWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2025Year of publication
- Publication date
-
2025-06-11Full publication date if available
- Authors
-
Luca Mastorino, Paolo Dapavo, Michela Ortoncelli, Eleonora Bongiovanni, Yingying Liao, Margherita Pelucchi, Francesco Leo, Pietro Quaglino, Simone RiberoList of authors in order
- Landing page
-
https://doi.org/10.1093/ced/llaf250Publisher landing page
- PDF URL
-
https://academic.oup.com/ced/advance-article-pdf/doi/10.1093/ced/llaf250/63472727/llaf250.pdfDirect link to full text PDF
- Open access
-
YesWhether a free full text is available
- OA status
-
hybridOpen access status per OpenAlex
- OA URL
-
https://academic.oup.com/ced/advance-article-pdf/doi/10.1093/ced/llaf250/63472727/llaf250.pdfDirect OA link when available
- Concepts
-
Secukinumab, Medicine, Dermatology, Psoriasis, Plaque psoriasis, Ixekizumab, Pharmacology, Psoriatic arthritisTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
0Total citation count in OpenAlex
- References (count)
-
18Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4411194368 |
|---|---|
| doi | https://doi.org/10.1093/ced/llaf250 |
| ids.doi | https://doi.org/10.1093/ced/llaf250 |
| ids.pmid | https://pubmed.ncbi.nlm.nih.gov/40499920 |
| ids.openalex | https://openalex.org/W4411194368 |
| fwci | 0.0 |
| mesh[0].qualifier_ui | |
| mesh[0].descriptor_ui | D006801 |
| mesh[0].is_major_topic | False |
| mesh[0].qualifier_name | |
| mesh[0].descriptor_name | Humans |
| mesh[1].qualifier_ui | Q000188 |
| mesh[1].descriptor_ui | D011565 |
| mesh[1].is_major_topic | True |
| mesh[1].qualifier_name | drug therapy |
| mesh[1].descriptor_name | Psoriasis |
| mesh[2].qualifier_ui | Q000008 |
| mesh[2].descriptor_ui | D061067 |
| mesh[2].is_major_topic | True |
| mesh[2].qualifier_name | administration & dosage |
| mesh[2].descriptor_name | Antibodies, Monoclonal, Humanized |
| mesh[3].qualifier_ui | |
| mesh[3].descriptor_ui | D008297 |
| mesh[3].is_major_topic | False |
| mesh[3].qualifier_name | |
| mesh[3].descriptor_name | Male |
| mesh[4].qualifier_ui | |
| mesh[4].descriptor_ui | D005260 |
| mesh[4].is_major_topic | False |
| mesh[4].qualifier_name | |
| mesh[4].descriptor_name | Female |
| mesh[5].qualifier_ui | |
| mesh[5].descriptor_ui | D012189 |
| mesh[5].is_major_topic | False |
| mesh[5].qualifier_name | |
| mesh[5].descriptor_name | Retrospective Studies |
| mesh[6].qualifier_ui | |
| mesh[6].descriptor_ui | D008875 |
| mesh[6].is_major_topic | False |
| mesh[6].qualifier_name | |
| mesh[6].descriptor_name | Middle Aged |
| mesh[7].qualifier_ui | |
| mesh[7].descriptor_ui | D000328 |
| mesh[7].is_major_topic | False |
| mesh[7].qualifier_name | |
| mesh[7].descriptor_name | Adult |
| mesh[8].qualifier_ui | Q000008 |
| mesh[8].descriptor_ui | D003879 |
| mesh[8].is_major_topic | True |
| mesh[8].qualifier_name | administration & dosage |
| mesh[8].descriptor_name | Dermatologic Agents |
| mesh[9].qualifier_ui | |
| mesh[9].descriptor_ui | D016896 |
| mesh[9].is_major_topic | False |
| mesh[9].qualifier_name | |
| mesh[9].descriptor_name | Treatment Outcome |
| mesh[10].qualifier_ui | |
| mesh[10].descriptor_ui | D000368 |
| mesh[10].is_major_topic | False |
| mesh[10].qualifier_name | |
| mesh[10].descriptor_name | Aged |
| mesh[11].qualifier_ui | |
| mesh[11].descriptor_ui | D004334 |
| mesh[11].is_major_topic | False |
| mesh[11].qualifier_name | |
| mesh[11].descriptor_name | Drug Administration Schedule |
| mesh[12].qualifier_ui | |
| mesh[12].descriptor_ui | D004305 |
| mesh[12].is_major_topic | False |
| mesh[12].qualifier_name | |
| mesh[12].descriptor_name | Dose-Response Relationship, Drug |
| mesh[13].qualifier_ui | |
| mesh[13].descriptor_ui | D006801 |
| mesh[13].is_major_topic | False |
| mesh[13].qualifier_name | |
| mesh[13].descriptor_name | Humans |
| mesh[14].qualifier_ui | Q000188 |
| mesh[14].descriptor_ui | D011565 |
| mesh[14].is_major_topic | True |
| mesh[14].qualifier_name | drug therapy |
| mesh[14].descriptor_name | Psoriasis |
| mesh[15].qualifier_ui | Q000008 |
| mesh[15].descriptor_ui | D061067 |
| mesh[15].is_major_topic | True |
| mesh[15].qualifier_name | administration & dosage |
| mesh[15].descriptor_name | Antibodies, Monoclonal, Humanized |
| mesh[16].qualifier_ui | |
| mesh[16].descriptor_ui | D008297 |
| mesh[16].is_major_topic | False |
| mesh[16].qualifier_name | |
| mesh[16].descriptor_name | Male |
| mesh[17].qualifier_ui | |
| mesh[17].descriptor_ui | D005260 |
| mesh[17].is_major_topic | False |
| mesh[17].qualifier_name | |
| mesh[17].descriptor_name | Female |
| mesh[18].qualifier_ui | |
| mesh[18].descriptor_ui | D012189 |
| mesh[18].is_major_topic | False |
| mesh[18].qualifier_name | |
| mesh[18].descriptor_name | Retrospective Studies |
| mesh[19].qualifier_ui | |
| mesh[19].descriptor_ui | D008875 |
| mesh[19].is_major_topic | False |
| mesh[19].qualifier_name | |
| mesh[19].descriptor_name | Middle Aged |
| mesh[20].qualifier_ui | |
| mesh[20].descriptor_ui | D000328 |
| mesh[20].is_major_topic | False |
| mesh[20].qualifier_name | |
| mesh[20].descriptor_name | Adult |
| mesh[21].qualifier_ui | Q000008 |
| mesh[21].descriptor_ui | D003879 |
| mesh[21].is_major_topic | True |
| mesh[21].qualifier_name | administration & dosage |
| mesh[21].descriptor_name | Dermatologic Agents |
| mesh[22].qualifier_ui | |
| mesh[22].descriptor_ui | D016896 |
| mesh[22].is_major_topic | False |
| mesh[22].qualifier_name | |
| mesh[22].descriptor_name | Treatment Outcome |
| mesh[23].qualifier_ui | |
| mesh[23].descriptor_ui | D000368 |
| mesh[23].is_major_topic | False |
| mesh[23].qualifier_name | |
| mesh[23].descriptor_name | Aged |
| mesh[24].qualifier_ui | |
| mesh[24].descriptor_ui | D004334 |
| mesh[24].is_major_topic | False |
| mesh[24].qualifier_name | |
| mesh[24].descriptor_name | Drug Administration Schedule |
| mesh[25].qualifier_ui | |
| mesh[25].descriptor_ui | D004305 |
| mesh[25].is_major_topic | False |
| mesh[25].qualifier_name | |
| mesh[25].descriptor_name | Dose-Response Relationship, Drug |
| type | article |
| title | Dose modulation strategies in patients with psoriasis: real-world comparison between secukinumab and brodalumab for up to 1 year after dose spacing |
| biblio.issue | 11 |
| biblio.volume | 50 |
| biblio.last_page | 2178 |
| biblio.first_page | 2172 |
| topics[0].id | https://openalex.org/T10469 |
| topics[0].field.id | https://openalex.org/fields/24 |
| topics[0].field.display_name | Immunology and Microbiology |
| topics[0].score | 0.9984999895095825 |
| topics[0].domain.id | https://openalex.org/domains/1 |
| topics[0].domain.display_name | Life Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2403 |
| topics[0].subfield.display_name | Immunology |
| topics[0].display_name | Psoriasis: Treatment and Pathogenesis |
| topics[1].id | https://openalex.org/T10804 |
| topics[1].field.id | https://openalex.org/fields/20 |
| topics[1].field.display_name | Economics, Econometrics and Finance |
| topics[1].score | 0.9930999875068665 |
| topics[1].domain.id | https://openalex.org/domains/2 |
| topics[1].domain.display_name | Social Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2002 |
| topics[1].subfield.display_name | Economics and Econometrics |
| topics[1].display_name | Health Systems, Economic Evaluations, Quality of Life |
| topics[2].id | https://openalex.org/T11092 |
| topics[2].field.id | https://openalex.org/fields/27 |
| topics[2].field.display_name | Medicine |
| topics[2].score | 0.9909999966621399 |
| topics[2].domain.id | https://openalex.org/domains/4 |
| topics[2].domain.display_name | Health Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2745 |
| topics[2].subfield.display_name | Rheumatology |
| topics[2].display_name | Spondyloarthritis Studies and Treatments |
| is_xpac | False |
| apc_list | |
| apc_paid | |
| concepts[0].id | https://openalex.org/C2779786854 |
| concepts[0].level | 4 |
| concepts[0].score | 0.9715609550476074 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q7444755 |
| concepts[0].display_name | Secukinumab |
| concepts[1].id | https://openalex.org/C71924100 |
| concepts[1].level | 0 |
| concepts[1].score | 0.6845756769180298 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[1].display_name | Medicine |
| concepts[2].id | https://openalex.org/C16005928 |
| concepts[2].level | 1 |
| concepts[2].score | 0.6486691236495972 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q171171 |
| concepts[2].display_name | Dermatology |
| concepts[3].id | https://openalex.org/C2780564577 |
| concepts[3].level | 2 |
| concepts[3].score | 0.5670190453529358 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q179945 |
| concepts[3].display_name | Psoriasis |
| concepts[4].id | https://openalex.org/C3020604521 |
| concepts[4].level | 3 |
| concepts[4].score | 0.42659008502960205 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q179945 |
| concepts[4].display_name | Plaque psoriasis |
| concepts[5].id | https://openalex.org/C2779745271 |
| concepts[5].level | 5 |
| concepts[5].score | 0.4238035976886749 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q13574436 |
| concepts[5].display_name | Ixekizumab |
| concepts[6].id | https://openalex.org/C98274493 |
| concepts[6].level | 1 |
| concepts[6].score | 0.3379286229610443 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q128406 |
| concepts[6].display_name | Pharmacology |
| concepts[7].id | https://openalex.org/C2776260265 |
| concepts[7].level | 3 |
| concepts[7].score | 0.28303825855255127 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q511097 |
| concepts[7].display_name | Psoriatic arthritis |
| keywords[0].id | https://openalex.org/keywords/secukinumab |
| keywords[0].score | 0.9715609550476074 |
| keywords[0].display_name | Secukinumab |
| keywords[1].id | https://openalex.org/keywords/medicine |
| keywords[1].score | 0.6845756769180298 |
| keywords[1].display_name | Medicine |
| keywords[2].id | https://openalex.org/keywords/dermatology |
| keywords[2].score | 0.6486691236495972 |
| keywords[2].display_name | Dermatology |
| keywords[3].id | https://openalex.org/keywords/psoriasis |
| keywords[3].score | 0.5670190453529358 |
| keywords[3].display_name | Psoriasis |
| keywords[4].id | https://openalex.org/keywords/plaque-psoriasis |
| keywords[4].score | 0.42659008502960205 |
| keywords[4].display_name | Plaque psoriasis |
| keywords[5].id | https://openalex.org/keywords/ixekizumab |
| keywords[5].score | 0.4238035976886749 |
| keywords[5].display_name | Ixekizumab |
| keywords[6].id | https://openalex.org/keywords/pharmacology |
| keywords[6].score | 0.3379286229610443 |
| keywords[6].display_name | Pharmacology |
| keywords[7].id | https://openalex.org/keywords/psoriatic-arthritis |
| keywords[7].score | 0.28303825855255127 |
| keywords[7].display_name | Psoriatic arthritis |
| language | en |
| locations[0].id | doi:10.1093/ced/llaf250 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S80252431 |
| locations[0].source.issn | 0307-6938, 1365-2230 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | False |
| locations[0].source.issn_l | 0307-6938 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | False |
| locations[0].source.display_name | Clinical and Experimental Dermatology |
| locations[0].source.host_organization | https://openalex.org/P4310311648 |
| locations[0].source.host_organization_name | Oxford University Press |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310311648, https://openalex.org/P4310311647 |
| locations[0].source.host_organization_lineage_names | Oxford University Press, University of Oxford |
| locations[0].license | cc-by |
| locations[0].pdf_url | https://academic.oup.com/ced/advance-article-pdf/doi/10.1093/ced/llaf250/63472727/llaf250.pdf |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | https://openalex.org/licenses/cc-by |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Clinical and Experimental Dermatology |
| locations[0].landing_page_url | https://doi.org/10.1093/ced/llaf250 |
| locations[1].id | pmid:40499920 |
| locations[1].is_oa | False |
| locations[1].source.id | https://openalex.org/S4306525036 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | PubMed |
| locations[1].source.host_organization | https://openalex.org/I1299303238 |
| locations[1].source.host_organization_name | National Institutes of Health |
| locations[1].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | publishedVersion |
| locations[1].raw_type | |
| locations[1].license_id | |
| locations[1].is_accepted | True |
| locations[1].is_published | True |
| locations[1].raw_source_name | Clinical and experimental dermatology |
| locations[1].landing_page_url | https://pubmed.ncbi.nlm.nih.gov/40499920 |
| indexed_in | crossref, pubmed |
| authorships[0].author.id | https://openalex.org/A5001379149 |
| authorships[0].author.orcid | https://orcid.org/0000-0001-7386-3219 |
| authorships[0].author.display_name | Luca Mastorino |
| authorships[0].countries | IT |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I55143463 |
| authorships[0].affiliations[0].raw_affiliation_string | Dermatology Clinic, Department of Medical Sciences, University of Turin, Turin, Italy |
| authorships[0].institutions[0].id | https://openalex.org/I55143463 |
| authorships[0].institutions[0].ror | https://ror.org/048tbm396 |
| authorships[0].institutions[0].type | education |
| authorships[0].institutions[0].lineage | https://openalex.org/I55143463 |
| authorships[0].institutions[0].country_code | IT |
| authorships[0].institutions[0].display_name | University of Turin |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Luca Mastorino |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | Dermatology Clinic, Department of Medical Sciences, University of Turin, Turin, Italy |
| authorships[1].author.id | https://openalex.org/A5035425594 |
| authorships[1].author.orcid | |
| authorships[1].author.display_name | Paolo Dapavo |
| authorships[1].countries | IT |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I55143463 |
| authorships[1].affiliations[0].raw_affiliation_string | Dermatology Clinic, Department of Medical Sciences, University of Turin, Turin, Italy |
| authorships[1].institutions[0].id | https://openalex.org/I55143463 |
| authorships[1].institutions[0].ror | https://ror.org/048tbm396 |
| authorships[1].institutions[0].type | education |
| authorships[1].institutions[0].lineage | https://openalex.org/I55143463 |
| authorships[1].institutions[0].country_code | IT |
| authorships[1].institutions[0].display_name | University of Turin |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Paolo Dapavo |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | Dermatology Clinic, Department of Medical Sciences, University of Turin, Turin, Italy |
| authorships[2].author.id | https://openalex.org/A5063124211 |
| authorships[2].author.orcid | |
| authorships[2].author.display_name | Michela Ortoncelli |
| authorships[2].countries | IT |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I55143463 |
| authorships[2].affiliations[0].raw_affiliation_string | Dermatology Clinic, Department of Medical Sciences, University of Turin, Turin, Italy |
| authorships[2].institutions[0].id | https://openalex.org/I55143463 |
| authorships[2].institutions[0].ror | https://ror.org/048tbm396 |
| authorships[2].institutions[0].type | education |
| authorships[2].institutions[0].lineage | https://openalex.org/I55143463 |
| authorships[2].institutions[0].country_code | IT |
| authorships[2].institutions[0].display_name | University of Turin |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Michela Ortoncelli |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | Dermatology Clinic, Department of Medical Sciences, University of Turin, Turin, Italy |
| authorships[3].author.id | https://openalex.org/A5059004340 |
| authorships[3].author.orcid | https://orcid.org/0009-0007-1915-9993 |
| authorships[3].author.display_name | Eleonora Bongiovanni |
| authorships[3].countries | IT |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I55143463 |
| authorships[3].affiliations[0].raw_affiliation_string | Dermatology Clinic, Department of Medical Sciences, University of Turin, Turin, Italy |
| authorships[3].institutions[0].id | https://openalex.org/I55143463 |
| authorships[3].institutions[0].ror | https://ror.org/048tbm396 |
| authorships[3].institutions[0].type | education |
| authorships[3].institutions[0].lineage | https://openalex.org/I55143463 |
| authorships[3].institutions[0].country_code | IT |
| authorships[3].institutions[0].display_name | University of Turin |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Eleonora Bongiovanni |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | Dermatology Clinic, Department of Medical Sciences, University of Turin, Turin, Italy |
| authorships[4].author.id | https://openalex.org/A5113275429 |
| authorships[4].author.orcid | https://orcid.org/0009-0002-5413-973X |
| authorships[4].author.display_name | Yingying Liao |
| authorships[4].countries | IT |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I55143463 |
| authorships[4].affiliations[0].raw_affiliation_string | Dermatology Clinic, Department of Medical Sciences, University of Turin, Turin, Italy |
| authorships[4].institutions[0].id | https://openalex.org/I55143463 |
| authorships[4].institutions[0].ror | https://ror.org/048tbm396 |
| authorships[4].institutions[0].type | education |
| authorships[4].institutions[0].lineage | https://openalex.org/I55143463 |
| authorships[4].institutions[0].country_code | IT |
| authorships[4].institutions[0].display_name | University of Turin |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Yingying Liao |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | Dermatology Clinic, Department of Medical Sciences, University of Turin, Turin, Italy |
| authorships[5].author.id | https://openalex.org/A5118120394 |
| authorships[5].author.orcid | |
| authorships[5].author.display_name | Margherita Pelucchi |
| authorships[5].countries | IT |
| authorships[5].affiliations[0].institution_ids | https://openalex.org/I55143463 |
| authorships[5].affiliations[0].raw_affiliation_string | Dermatology Clinic, Department of Medical Sciences, University of Turin, Turin, Italy |
| authorships[5].institutions[0].id | https://openalex.org/I55143463 |
| authorships[5].institutions[0].ror | https://ror.org/048tbm396 |
| authorships[5].institutions[0].type | education |
| authorships[5].institutions[0].lineage | https://openalex.org/I55143463 |
| authorships[5].institutions[0].country_code | IT |
| authorships[5].institutions[0].display_name | University of Turin |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | Margherita Pelucchi |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | Dermatology Clinic, Department of Medical Sciences, University of Turin, Turin, Italy |
| authorships[6].author.id | https://openalex.org/A5007050103 |
| authorships[6].author.orcid | https://orcid.org/0000-0003-0267-8272 |
| authorships[6].author.display_name | Francesco Leo |
| authorships[6].countries | IT |
| authorships[6].affiliations[0].institution_ids | https://openalex.org/I55143463 |
| authorships[6].affiliations[0].raw_affiliation_string | Dermatology Clinic, Department of Medical Sciences, University of Turin, Turin, Italy |
| authorships[6].institutions[0].id | https://openalex.org/I55143463 |
| authorships[6].institutions[0].ror | https://ror.org/048tbm396 |
| authorships[6].institutions[0].type | education |
| authorships[6].institutions[0].lineage | https://openalex.org/I55143463 |
| authorships[6].institutions[0].country_code | IT |
| authorships[6].institutions[0].display_name | University of Turin |
| authorships[6].author_position | middle |
| authorships[6].raw_author_name | Francesco Leo |
| authorships[6].is_corresponding | False |
| authorships[6].raw_affiliation_strings | Dermatology Clinic, Department of Medical Sciences, University of Turin, Turin, Italy |
| authorships[7].author.id | https://openalex.org/A5066790760 |
| authorships[7].author.orcid | https://orcid.org/0000-0003-4185-9586 |
| authorships[7].author.display_name | Pietro Quaglino |
| authorships[7].countries | IT |
| authorships[7].affiliations[0].institution_ids | https://openalex.org/I55143463 |
| authorships[7].affiliations[0].raw_affiliation_string | Dermatology Clinic, Department of Medical Sciences, University of Turin, Turin, Italy |
| authorships[7].institutions[0].id | https://openalex.org/I55143463 |
| authorships[7].institutions[0].ror | https://ror.org/048tbm396 |
| authorships[7].institutions[0].type | education |
| authorships[7].institutions[0].lineage | https://openalex.org/I55143463 |
| authorships[7].institutions[0].country_code | IT |
| authorships[7].institutions[0].display_name | University of Turin |
| authorships[7].author_position | middle |
| authorships[7].raw_author_name | Pietro Quaglino |
| authorships[7].is_corresponding | False |
| authorships[7].raw_affiliation_strings | Dermatology Clinic, Department of Medical Sciences, University of Turin, Turin, Italy |
| authorships[8].author.id | https://openalex.org/A5005909861 |
| authorships[8].author.orcid | https://orcid.org/0000-0002-0098-1406 |
| authorships[8].author.display_name | Simone Ribero |
| authorships[8].countries | IT |
| authorships[8].affiliations[0].institution_ids | https://openalex.org/I55143463 |
| authorships[8].affiliations[0].raw_affiliation_string | Dermatology Clinic, Department of Medical Sciences, University of Turin, Turin, Italy |
| authorships[8].institutions[0].id | https://openalex.org/I55143463 |
| authorships[8].institutions[0].ror | https://ror.org/048tbm396 |
| authorships[8].institutions[0].type | education |
| authorships[8].institutions[0].lineage | https://openalex.org/I55143463 |
| authorships[8].institutions[0].country_code | IT |
| authorships[8].institutions[0].display_name | University of Turin |
| authorships[8].author_position | last |
| authorships[8].raw_author_name | Simone Ribero |
| authorships[8].is_corresponding | False |
| authorships[8].raw_affiliation_strings | Dermatology Clinic, Department of Medical Sciences, University of Turin, Turin, Italy |
| has_content.pdf | True |
| has_content.grobid_xml | True |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://academic.oup.com/ced/advance-article-pdf/doi/10.1093/ced/llaf250/63472727/llaf250.pdf |
| open_access.oa_status | hybrid |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Dose modulation strategies in patients with psoriasis: real-world comparison between secukinumab and brodalumab for up to 1 year after dose spacing |
| has_fulltext | True |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T10469 |
| primary_topic.field.id | https://openalex.org/fields/24 |
| primary_topic.field.display_name | Immunology and Microbiology |
| primary_topic.score | 0.9984999895095825 |
| primary_topic.domain.id | https://openalex.org/domains/1 |
| primary_topic.domain.display_name | Life Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2403 |
| primary_topic.subfield.display_name | Immunology |
| primary_topic.display_name | Psoriasis: Treatment and Pathogenesis |
| related_works | https://openalex.org/W3010318162, https://openalex.org/W3194237911, https://openalex.org/W2947953937, https://openalex.org/W4405727636, https://openalex.org/W4400020800, https://openalex.org/W4255011116, https://openalex.org/W3091779166, https://openalex.org/W3011866593, https://openalex.org/W2923455736, https://openalex.org/W4387014929 |
| cited_by_count | 0 |
| locations_count | 2 |
| best_oa_location.id | doi:10.1093/ced/llaf250 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S80252431 |
| best_oa_location.source.issn | 0307-6938, 1365-2230 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | False |
| best_oa_location.source.issn_l | 0307-6938 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | False |
| best_oa_location.source.display_name | Clinical and Experimental Dermatology |
| best_oa_location.source.host_organization | https://openalex.org/P4310311648 |
| best_oa_location.source.host_organization_name | Oxford University Press |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310311648, https://openalex.org/P4310311647 |
| best_oa_location.source.host_organization_lineage_names | Oxford University Press, University of Oxford |
| best_oa_location.license | cc-by |
| best_oa_location.pdf_url | https://academic.oup.com/ced/advance-article-pdf/doi/10.1093/ced/llaf250/63472727/llaf250.pdf |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | Clinical and Experimental Dermatology |
| best_oa_location.landing_page_url | https://doi.org/10.1093/ced/llaf250 |
| primary_location.id | doi:10.1093/ced/llaf250 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S80252431 |
| primary_location.source.issn | 0307-6938, 1365-2230 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | False |
| primary_location.source.issn_l | 0307-6938 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | False |
| primary_location.source.display_name | Clinical and Experimental Dermatology |
| primary_location.source.host_organization | https://openalex.org/P4310311648 |
| primary_location.source.host_organization_name | Oxford University Press |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310311648, https://openalex.org/P4310311647 |
| primary_location.source.host_organization_lineage_names | Oxford University Press, University of Oxford |
| primary_location.license | cc-by |
| primary_location.pdf_url | https://academic.oup.com/ced/advance-article-pdf/doi/10.1093/ced/llaf250/63472727/llaf250.pdf |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | https://openalex.org/licenses/cc-by |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Clinical and Experimental Dermatology |
| primary_location.landing_page_url | https://doi.org/10.1093/ced/llaf250 |
| publication_date | 2025-06-11 |
| publication_year | 2025 |
| referenced_works | https://openalex.org/W4294752278, https://openalex.org/W3028355101, https://openalex.org/W4390225870, https://openalex.org/W4391160346, https://openalex.org/W4385684691, https://openalex.org/W4317780848, https://openalex.org/W2593486984, https://openalex.org/W3123517269, https://openalex.org/W4224518760, https://openalex.org/W4378976510, https://openalex.org/W4312210153, https://openalex.org/W6857876712, https://openalex.org/W4393276317, https://openalex.org/W2945527657, https://openalex.org/W2326643498, https://openalex.org/W4312105719, https://openalex.org/W4390542832, https://openalex.org/W3204990173 |
| referenced_works_count | 18 |
| abstract_inverted_index.1 | 311 |
| abstract_inverted_index.a | 73, 79, 137, 256 |
| abstract_inverted_index.1, | 198 |
| abstract_inverted_index.12 | 219 |
| abstract_inverted_index.31 | 125 |
| abstract_inverted_index.35 | 140 |
| abstract_inverted_index.49 | 132 |
| abstract_inverted_index.90 | 193 |
| abstract_inverted_index.At | 146 |
| abstract_inverted_index.No | 268, 317 |
| abstract_inverted_index.To | 58 |
| abstract_inverted_index.an | 301 |
| abstract_inverted_index.at | 175, 209, 218, 276 |
| abstract_inverted_index.by | 112, 118, 173 |
| abstract_inverted_index.in | 11, 72, 163, 249, 270, 293, 313 |
| abstract_inverted_index.is | 7, 78 |
| abstract_inverted_index.mg | 33 |
| abstract_inverted_index.of | 5, 8, 39, 66, 68, 85, 89, 104, 120, 139, 178, 203, 212, 227, 235, 238, 251, 261, 290, 315 |
| abstract_inverted_index.or | 36, 99 |
| abstract_inverted_index.to | 161, 241, 310 |
| abstract_inverted_index.up | 309 |
| abstract_inverted_index.(20 | 237 |
| abstract_inverted_index.0.1 | 162 |
| abstract_inverted_index.0.7 | 160 |
| abstract_inverted_index.100 | 168, 246 |
| abstract_inverted_index.40% | 314 |
| abstract_inverted_index.50% | 119 |
| abstract_inverted_index.59% | 265 |
| abstract_inverted_index.80) | 239 |
| abstract_inverted_index.91% | 174 |
| abstract_inverted_index.99% | 200 |
| abstract_inverted_index.D-S | 67, 96, 113, 179, 229, 260, 280, 327 |
| abstract_inverted_index.The | 223 |
| abstract_inverted_index.and | 20, 41, 63, 70, 101, 131, 152, 180, 194, 201, 272, 297, 323 |
| abstract_inverted_index.any | 277 |
| abstract_inverted_index.are | 55 |
| abstract_inverted_index.for | 191, 266, 308 |
| abstract_inverted_index.the | 3, 28, 32, 37, 46, 61, 86, 102, 115, 121, 142, 148, 164, 176, 184, 210, 228, 242, 284, 326 |
| abstract_inverted_index.two | 285 |
| abstract_inverted_index.was | 156, 171, 231, 247 |
| abstract_inverted_index.≤ | 197 |
| abstract_inverted_index.0.1, | 157 |
| abstract_inverted_index.100% | 202 |
| abstract_inverted_index.66%, | 232 |
| abstract_inverted_index.78%, | 262 |
| abstract_inverted_index.Area | 151 |
| abstract_inverted_index.D-S, | 147 |
| abstract_inverted_index.D-S. | 105, 145, 213, 222 |
| abstract_inverted_index.PASI | 167, 192, 196, 245, 274 |
| abstract_inverted_index.This | 15, 77 |
| abstract_inverted_index.data | 51 |
| abstract_inverted_index.date | 177 |
| abstract_inverted_index.dose | 17, 21, 42, 53, 110 |
| abstract_inverted_index.drug | 64, 225, 257 |
| abstract_inverted_index.from | 159 |
| abstract_inverted_index.mean | 138, 149, 271 |
| abstract_inverted_index.over | 183 |
| abstract_inverted_index.seen | 190 |
| abstract_inverted_index.that | 305 |
| abstract_inverted_index.time | 211 |
| abstract_inverted_index.were | 127, 189, 216, 281, 319 |
| abstract_inverted_index.with | 13, 82, 91, 97, 114, 129, 134, 199, 233, 264, 295 |
| abstract_inverted_index.year | 312 |
| abstract_inverted_index.(100% | 169 |
| abstract_inverted_index.(39%) | 126 |
| abstract_inverted_index.(61%) | 133 |
| abstract_inverted_index.After | 136 |
| abstract_inverted_index.Index | 154 |
| abstract_inverted_index.These | 214 |
| abstract_inverted_index.after | 221, 259, 279 |
| abstract_inverted_index.dose, | 31 |
| abstract_inverted_index.found | 282 |
| abstract_inverted_index.goals | 208 |
| abstract_inverted_index.ratio | 35 |
| abstract_inverted_index.seems | 300 |
| abstract_inverted_index.study | 81 |
| abstract_inverted_index.these | 207, 252 |
| abstract_inverted_index.year. | 166, 186 |
| abstract_inverted_index.(D-S), | 44 |
| abstract_inverted_index.(PASI) | 155 |
| abstract_inverted_index.Eighty | 107 |
| abstract_inverted_index.cases. | 253 |
| abstract_inverted_index.cohort | 80 |
| abstract_inverted_index.during | 325 |
| abstract_inverted_index.kg−1 | 34 |
| abstract_inverted_index.levels | 215 |
| abstract_inverted_index.months | 220 |
| abstract_inverted_index.number | 38 |
| abstract_inverted_index.range. | 123 |
| abstract_inverted_index.scores | 275 |
| abstract_inverted_index.showed | 255 |
| abstract_inverted_index.single | 29 |
| abstract_inverted_index.stable | 182 |
| abstract_inverted_index.trends | 188 |
| abstract_inverted_index.Methods | 76 |
| abstract_inverted_index.Results | 106 |
| abstract_inverted_index.Similar | 187 |
| abstract_inverted_index.analyse | 60 |
| abstract_inverted_index.between | 48, 283, 321 |
| abstract_inverted_index.disease | 299 |
| abstract_inverted_index.dosage. | 244 |
| abstract_inverted_index.general | 87 |
| abstract_inverted_index.include | 26 |
| abstract_inverted_index.months, | 141 |
| abstract_inverted_index.ranging | 158 |
| abstract_inverted_index.regimen | 4, 230 |
| abstract_inverted_index.spacing | 43 |
| abstract_inverted_index.treated | 128 |
| abstract_inverted_index.12-month | 224 |
| abstract_inverted_index.Abstract | 0 |
| abstract_inverted_index.Overall, | 124 |
| abstract_inverted_index.Severity | 153 |
| abstract_inverted_index.absolute | 195 |
| abstract_inverted_index.achieved | 172 |
| abstract_inverted_index.analysis | 84 |
| abstract_inverted_index.approved | 122 |
| abstract_inverted_index.biologic | 95 |
| abstract_inverted_index.compared | 263 |
| abstract_inverted_index.efficacy | 307 |
| abstract_inverted_index.includes | 16 |
| abstract_inverted_index.interest | 10 |
| abstract_inverted_index.interval | 47, 116 |
| abstract_inverted_index.lacking. | 56 |
| abstract_inverted_index.observed | 320 |
| abstract_inverted_index.patients | 12, 90, 108, 236, 294 |
| abstract_inverted_index.reducing | 27 |
| abstract_inverted_index.regained | 248 |
| abstract_inverted_index.regimen. | 328 |
| abstract_inverted_index.relative | 273 |
| abstract_inverted_index.remained | 181 |
| abstract_inverted_index.setting. | 75 |
| abstract_inverted_index.standard | 243 |
| abstract_inverted_index.strategy | 304 |
| abstract_inverted_index.survival | 65, 226, 258 |
| abstract_inverted_index.Psoriasis | 150 |
| abstract_inverted_index.Real-life | 50 |
| abstract_inverted_index.achieving | 206 |
| abstract_inverted_index.biologics | 6 |
| abstract_inverted_index.effective | 302 |
| abstract_inverted_index.extending | 45 |
| abstract_inverted_index.following | 165, 185 |
| abstract_inverted_index.increased | 117 |
| abstract_inverted_index.maintains | 306 |
| abstract_inverted_index.patients, | 204 |
| abstract_inverted_index.patients. | 316 |
| abstract_inverted_index.psoriasis | 92, 296 |
| abstract_inverted_index.reduction | 18 |
| abstract_inverted_index.regarding | 52 |
| abstract_inverted_index.returning | 240 |
| abstract_inverted_index.timepoint | 278 |
| abstract_inverted_index.underwent | 109, 144 |
| abstract_inverted_index.Background | 1 |
| abstract_inverted_index.Modulating | 2 |
| abstract_inverted_index.Objectives | 57 |
| abstract_inverted_index.brodalumab | 71, 100, 324 |
| abstract_inverted_index.controlled | 298 |
| abstract_inverted_index.increasing | 9 |
| abstract_inverted_index.inhibitors | 292 |
| abstract_inverted_index.maintained | 217 |
| abstract_inverted_index.modulation | 111, 289 |
| abstract_inverted_index.population | 143 |
| abstract_inverted_index.psoriasis. | 14 |
| abstract_inverted_index.real-world | 74 |
| abstract_inverted_index.strategies | 25 |
| abstract_inverted_index.two-thirds | 250 |
| abstract_inverted_index.undergoing | 93 |
| abstract_inverted_index.Conclusions | 287 |
| abstract_inverted_index.Secukinumab | 254 |
| abstract_inverted_index.Therapeutic | 288 |
| abstract_inverted_index.brodalumab. | 135, 267 |
| abstract_inverted_index.differences | 269, 318 |
| abstract_inverted_index.injections, | 40 |
| abstract_inverted_index.one-quarter | 234 |
| abstract_inverted_index.secukinumab | 69, 98, 130, 322 |
| abstract_inverted_index.therapeutic | 30, 94, 303 |
| abstract_inverted_index.treatments. | 286 |
| abstract_inverted_index.augmentation | 22 |
| abstract_inverted_index.improvement) | 170 |
| abstract_inverted_index.(escalation). | 23 |
| abstract_inverted_index.De-escalation | 24 |
| abstract_inverted_index.de-escalation | 54 |
| abstract_inverted_index.effectiveness | 62, 103 |
| abstract_inverted_index.respectively, | 205 |
| abstract_inverted_index.retrospective | 83 |
| abstract_inverted_index.interleukin-17 | 291 |
| abstract_inverted_index.(de-escalation) | 19 |
| abstract_inverted_index.characteristics | 88 |
| abstract_inverted_index.retrospectively | 59 |
| abstract_inverted_index.administrations. | 49 |
| cited_by_percentile_year | |
| countries_distinct_count | 1 |
| institutions_distinct_count | 9 |
| citation_normalized_percentile.value | 0.24729192 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |